Diseases · Entity Annotation Prototype (beta)

2articles mentioning diseases

4disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: locally advanced/metastatic tumours ×

locally advanced/metastatic tumours

This disease is selected. Its supporting articles are shown below.

locally advanced/metastatic tumours2

Articles mentioning locally advanced/metastatic tumours

2 articles · page 1 of 1

First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours

bmjonc · abstract · 2026-02-17 · 2 matching annotations

87.4%

solid tumours locally advanced/metastatic tumours W0180 pembrolizumab

…erapy arm, cohorts of patients with locally advanced/metastatic solid tumours received once-weekly W0180 at increasing doses (from 3.5 to 600…

First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours

bmjonc · full text · 2026-02-17 · 2 matching annotations

86.0%

squamous cell carcinoma prostate cancer solid tumours Stage IV malignant melanoma locally advanced or metastatic solid tumours locally advanced/metastatic tumours

… pan-cytokeratin; PSGL1, P-selectin glycoprotein ligand-1; SCC, squamous cell carcinoma; SD, stable disease; VISTA, V domain-containing immunoglobulin …

Browse diseases

locally advanced/metastatic tumours

Articles mentioning locally advanced/metastatic tumours

First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours

First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours